Denali Therapeutics Inc.
DNLINasdaqCIK 1714899HealthcareFiscal year ends Dec 31
Reports and events: 150 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0616:08 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001714899-26-000097 |
| 2026-08-0616:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000096 |
| 2026-07-2821:01 ET | 8-K | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001714899-26-000086 |
| 2026-06-1808:01 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-26-000081 |
| 2026-06-0418:43 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-26-000074 |
| 2026-05-2218:17 ET | 8-K | 7.01 Regulation FD disclosure | 0001714899-26-000070 |
| 2026-05-0716:12 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001714899-26-000064 |
| 2026-05-0716:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000062 |
| 2026-04-2116:31 ET | DEF 14A | Proxy statementPeriod 2025-12-31 | 0001714899-26-000054 |
| 2026-04-0314:43 ET | 8-K | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001714899-26-000042 |
| 2026-03-3108:30 ET | 8-K | 2.03 New direct financial obligation; 7.01 Regulation FD disclosure | 0001714899-26-000036 |
| 2026-03-2515:13 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-26-000030 |
| 2026-02-2616:11 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001714899-26-000021 |
| 2026-02-2616:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000020 |
| 2026-01-0608:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-26-000004 |
| 2025-12-1017:21 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-056363 |
| 2025-12-0407:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001714899-25-000209 |
| 2025-12-0407:01 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001714899-25-000208 |
| 2025-11-0616:05 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001714899-25-000193 |
| 2025-11-0616:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000192 |
| 2025-10-1408:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000180 |
| 2025-08-1116:25 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001714899-25-000170 |
| 2025-08-1116:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000167 |
| 2025-07-0708:04 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000146 |
| 2025-06-0316:05 ET | 8-K | 1.01 Entry into a material agreement; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-25-000128 |
| 2025-05-0616:04 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001714899-25-000105 |
| 2025-05-0616:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000104 |
| 2025-04-1716:05 ET | DEF 14A | Proxy statementPeriod 2024-12-31 | 0001714899-25-000087 |
| 2025-04-0208:02 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000077 |
| 2025-03-0517:26 ET | 8-K | 7.01 Regulation FD disclosure | 0001714899-25-000072 |
| 2025-02-2716:12 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000067 |
| 2025-02-2716:05 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001714899-25-000066 |
| 2025-01-1308:03 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000054 |
| 2025-01-0718:13 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000007 |
| 2024-11-1816:02 ET | 8-K | 5.03 Amendment to articles or bylaws | 0001714899-24-000233 |
| 2024-11-0616:17 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001714899-24-000216 |
| 2024-11-0616:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000215 |
| 2024-10-1016:02 ET | 8-K | 7.01 Regulation FD disclosure | 0001714899-24-000205 |
| 2024-08-0106:52 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001714899-24-000169 |
| 2024-08-0106:48 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000168 |
| 2024-05-3116:01 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-24-000125 |
| 2024-05-0716:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001714899-24-000121 |
| 2024-05-0716:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000120 |
| 2024-04-1816:03 ET | DEF 14A | Proxy statementPeriod 2023-12-31 | 0001714899-24-000110 |
| 2024-02-2820:16 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001714899-24-000086 |
| 2024-02-2708:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000076 |
| 2024-02-2708:03 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-24-000075 |
| 2024-02-1608:02 ET | 8-K | 7.01 Regulation FD disclosure | 0001714899-24-000065 |
| 2024-01-0808:06 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-24-000031 |
| 2023-11-0716:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001714899-23-000146 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.